FY2025 · ended Dec 31, 2025 · Revenue $1.49B, -14.3% YoY · Filed Feb 13, 2026
Nu Skin Enterprises, Inc. (NUS) files with the SEC under industry code 5122, Wholesale-Drugs, Proprietaries & Druggists' Sundries. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.5 billion and net income of $160.2 million. Free cash flow was $46.0 million. As of Jun 30, 2026 it held $191.4 million in cash and investments and $288.1 million in total debt.
Revenue (TTM)
$1.38B
-15.4% vs year-ago TTM
Net income (TTM)
$-216.39M
-314.6% vs year-ago TTM
Operating cash flow (TTM)
$50.81M
-45.6% vs year-ago TTM
Free cash flow (TTM)
$10.78M
-81.6% vs year-ago TTM
EPS (TTM)
$-4.36
-315.0% vs year-ago TTM
Dividend per share
$0.30
Shares outstanding
48.13M
-3.2% vs prior year
Net cash
$-96.71M
as of Jun 30, 2026
Operating margin
-0.8%
FY 2026
Company profile
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
- Listed as
- NUS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Provo, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 1021561
- Former names
- NU SKIN ENTERPRISES INC (until Sep 13, 2019); NU SKIN ASIA PACIFIC INC (until Aug 13, 1998); NU SKIN ASIA INC (until Sep 16, 1996)
Other Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
- Mckesson Corp MCK
- Cencora, Inc. COR
- Cardinal Health Inc CAH
- Herbalife Ltd. HLF
- EnerSyn Global Inc. ESYN
- Cosmos Health Inc. COSM
- DataMeds AI, Inc. MEDS
- Cellyan Biotechnology Co., Ltd HKPD
All 11 Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.5B | $1.7B | $2.0B | $2.2B | $2.7B |
| Operating income | $65.8M | -$151.6M | $48.3M | $110.8M | $234.0M |
| Net income | $160.2M | -$146.6M | $8.6M | $104.8M | $147.3M |
| Diluted EPS | $3.18 | -$2.95 | $0.17 | $2.07 | $2.86 |
| Operating cash flow | $80.3M | $111.7M | $118.6M | $108.1M | $141.6M |
| Free cash flow | $46.0M | $70.2M | $60.1M | $49.0M | $73.0M |
| Total assets | $1.4B | $1.5B | $1.8B | $1.8B | $1.9B |
| Total liabilities | $600.1M | $817.5M | $986.7M | $923.7M | $993.7M |
| Stockholders' equity | $805.2M | $651.5M | $822.0M | $897.3M | $912.8M |
| Cash and investments | $244.3M | $201.9M | $304.2M | $318.0M | $390.7M |
| Total debt | $308.6M | $479.1M | $607.5M | $519.4M | $504.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 21, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 29, 2026 | May 28, 2026 |
| 8-K |
Current report
Officer or director change
|
May 8, 2026 | May 6, 2026 |
All 1001 Nu Skin Enterprises, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.